loader image
Tuesday, May 7, 2024
82.5 F
McAllen
We Welcome your Press Release
- Advertisement -

Promising Drug to Treat Gastrointestinal Cancers

Translate to Spanish or other 102 languages!

The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function. Image for illustration purposes.
The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function. Image for illustration purposes.

Mega Doctor News

- Advertisement -

By Mayo Clinic 

Newswise — PHOENIX  Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.

Tanios Bekaii-Saab, M.D., an investigator from Mayo Clinic Cancer Center, has conducted research on adagrasib that has demonstrated promising clinical activity in patients with gastrointestinal cancers that harbor KRAS G12C mutations, including pancreatic cancer, biliary tract cancer and other upper gastrointestinal cancers. Dr. Bekaii-Saab recently presented the results of this research as part of the KRYSTAL-1 clinical trial (NCT03785249) at the American Society of Clinic Oncology’s Genitourinary Cancers Symposium.

- Advertisement -

“The prognosis for patients whose cancer harbors a KRAS gene mutation is particularly poor, and researchers’ attempts to target KRAS G12C, which represents less than 5% of all KRAS mutations in this group of cancers, have failed until only recently,” says Dr. Bekaii-Saab.

“Our data recently presented at ASCO GI (the symposium) showed that adagrasib not only inhibits cancers with a KRASG12C mutation effectively, but also showed promising clinical activity in patients with gastrointestinal cancers.”

Dr. Bekaii-Saab says the gastrointestinal cancers for all patients treated in this phase 2 cohort were controlled, with close to half showing evidence of significant and durable tumor shrinkage.

“These results were very impressive in treating a group of diseases that tend to have a particularly poor outcome,” says Dr. Bekaii-Saab. “We were pleasantly surprised by these findings, given that our previous experience with another similar agent was disappointing in this particular group of patients.”

- Advertisement -

He says research with adagrasib is ongoing. If these trends continue, the drug may eventually prove to be a new option for patients with pancreatic, biliary tract and other gastrointestinal cancers.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

TMA Elects Houston, North Texas, Central Texas, Panhandle Physicians to Board 

Physicians from across the state conducted the elections on Saturday during TexMed 2024, TMA’s annual conference, in Dallas.

TMA Bestows Highest Honor to Congressman Burgess 

“After serving the people of Texas as a physician for over 25 years and working on health care policies in Congress for the past 22 years, I’ve learned the health care system continues to grow and expand day by day,” said Dr. Burgess.

What’s health care like in rural America? 

There are plenty of reasons why 1 in 5 Americans live in rural areas.

Governor Abbott, THECB Announce Chair of Healthcare Workforce Task Force

“Victoria Ford brings a wealth of expertise in healthcare to this committee, and we look forward to the innovative solutions that will come out of the Healthcare Workforce Task Force in the fall,” said Commissioner of Higher Education Harrison Keller.
- Advertisement -
×